Copyright Reports & Markets. All rights reserved.

Global Antidiabetics Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Antidiabetics Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Antidiabetics Drug Market Size Growth Rate by Product
      • 1.4.2 Metformin (Biguanides)
      • 1.4.3 Insulin Sensitization Agent (TZD Use)
      • 1.4.4 Sulfonated Ideal Urea Class
      • 1.4.5 Meglitinides
      • 1.4.6 Alpha Glucosidase Inhibitors
    • 1.5 Market by End User
      • 1.5.1 Global Antidiabetics Drug Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Household
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Antidiabetics Drug Market Size
      • 2.1.1 Global Antidiabetics Drug Revenue 2014-2025
      • 2.1.2 Global Antidiabetics Drug Sales 2014-2025
    • 2.2 Antidiabetics Drug Growth Rate by Regions
      • 2.2.1 Global Antidiabetics Drug Sales by Regions
      • 2.2.2 Global Antidiabetics Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Antidiabetics Drug Sales by Manufacturers
      • 3.1.1 Antidiabetics Drug Sales by Manufacturers
      • 3.1.2 Antidiabetics Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Antidiabetics Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Antidiabetics Drug Revenue by Manufacturers
      • 3.2.1 Antidiabetics Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Antidiabetics Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Antidiabetics Drug Price by Manufacturers
    • 3.4 Antidiabetics Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Antidiabetics Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Antidiabetics Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Antidiabetics Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Antidiabetics Drug Sales by Product
    • 4.2 Global Antidiabetics Drug Revenue by Product
    • 4.3 Antidiabetics Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Antidiabetics Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Antidiabetics Drug by Countries
      • 6.1.1 North America Antidiabetics Drug Sales by Countries
      • 6.1.2 North America Antidiabetics Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Antidiabetics Drug by Product
    • 6.3 North America Antidiabetics Drug by End User

    7 Europe

    • 7.1 Europe Antidiabetics Drug by Countries
      • 7.1.1 Europe Antidiabetics Drug Sales by Countries
      • 7.1.2 Europe Antidiabetics Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Antidiabetics Drug by Product
    • 7.3 Europe Antidiabetics Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Antidiabetics Drug by Countries
      • 8.1.1 Asia Pacific Antidiabetics Drug Sales by Countries
      • 8.1.2 Asia Pacific Antidiabetics Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Antidiabetics Drug by Product
    • 8.3 Asia Pacific Antidiabetics Drug by End User

    9 Central & South America

    • 9.1 Central & South America Antidiabetics Drug by Countries
      • 9.1.1 Central & South America Antidiabetics Drug Sales by Countries
      • 9.1.2 Central & South America Antidiabetics Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Antidiabetics Drug by Product
    • 9.3 Central & South America Antidiabetics Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Antidiabetics Drug by Countries
      • 10.1.1 Middle East and Africa Antidiabetics Drug Sales by Countries
      • 10.1.2 Middle East and Africa Antidiabetics Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Antidiabetics Drug by Product
    • 10.3 Middle East and Africa Antidiabetics Drug by End User

    11 Company Profiles

    • 11.1 AstraZeneca
      • 11.1.1 AstraZeneca Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 AstraZeneca Antidiabetics Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 AstraZeneca Antidiabetics Drug Products Offered
      • 11.1.5 AstraZeneca Recent Development
    • 11.2 Bayer
      • 11.2.1 Bayer Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bayer Antidiabetics Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bayer Antidiabetics Drug Products Offered
      • 11.2.5 Bayer Recent Development
    • 11.3 Boehringer Ingelheim
      • 11.3.1 Boehringer Ingelheim Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Boehringer Ingelheim Antidiabetics Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Boehringer Ingelheim Antidiabetics Drug Products Offered
      • 11.3.5 Boehringer Ingelheim Recent Development
    • 11.4 Eli-Lilly
      • 11.4.1 Eli-Lilly Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Eli-Lilly Antidiabetics Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Eli-Lilly Antidiabetics Drug Products Offered
      • 11.4.5 Eli-Lilly Recent Development
    • 11.5 Johnson & Johnson
      • 11.5.1 Johnson & Johnson Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Johnson & Johnson Antidiabetics Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Johnson & Johnson Antidiabetics Drug Products Offered
      • 11.5.5 Johnson & Johnson Recent Development
    • 11.6 Merck
      • 11.6.1 Merck Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Merck Antidiabetics Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Merck Antidiabetics Drug Products Offered
      • 11.6.5 Merck Recent Development
    • 11.7 Novartis
      • 11.7.1 Novartis Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Novartis Antidiabetics Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Novartis Antidiabetics Drug Products Offered
      • 11.7.5 Novartis Recent Development
    • 11.8 Novo Nordisk
      • 11.8.1 Novo Nordisk Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Novo Nordisk Antidiabetics Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Novo Nordisk Antidiabetics Drug Products Offered
      • 11.8.5 Novo Nordisk Recent Development
    • 11.9 Sanofi
      • 11.9.1 Sanofi Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Sanofi Antidiabetics Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Sanofi Antidiabetics Drug Products Offered
      • 11.9.5 Sanofi Recent Development

    12 Future Forecast

    • 12.1 Antidiabetics Drug Market Forecast by Regions
      • 12.1.1 Global Antidiabetics Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Antidiabetics Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Antidiabetics Drug Market Forecast by Product
      • 12.2.1 Global Antidiabetics Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Antidiabetics Drug Revenue Forecast by Product 2019-2025
    • 12.3 Antidiabetics Drug Market Forecast by End User
    • 12.4 North America Antidiabetics Drug Forecast
    • 12.5 Europe Antidiabetics Drug Forecast
    • 12.6 Asia Pacific Antidiabetics Drug Forecast
    • 12.7 Central & South America Antidiabetics Drug Forecast
    • 12.8 Middle East and Africa Antidiabetics Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Antidiabetics Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Antidiabetics Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Antidiabetics Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Antidiabetics Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Antidiabetics Drug in these regions.
      This research report categorizes the global Antidiabetics Drug market by top players/brands, region, type and end user. This report also studies the global Antidiabetics Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      AstraZeneca
      Bayer
      Boehringer Ingelheim
      Eli-Lilly
      Johnson & Johnson
      Merck
      Novartis
      Novo Nordisk
      Sanofi

      Market size by Product
      Metformin (Biguanides)
      Insulin Sensitization Agent (TZD Use)
      Sulfonated Ideal Urea Class
      Meglitinides
      Alpha Glucosidase Inhibitors
      Market size by End User
      Hospital
      Household

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Antidiabetics Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Antidiabetics Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Antidiabetics Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Antidiabetics Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Antidiabetics Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Antidiabetics Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now